Onco Wiki / Indication

Anaplastic thyroid carcinoma (ATC) · line 1 · Paclitaxel + carboplatin (ATC, palliative 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy1
Trackstandard
Linked regimenREG-PACLITAXEL-CARBOPLATIN-ATC
IDIND-ATC-PACLITAXEL-CARBOPLATIN
TypeIndication
Statuspending_clinical_signoff
DiseasesDIS-THYROID-ANAPLASTIC
SourcesSRC-NCCN-THYROID-2025

Notes

STUB scaffold. Auto-generated minimal indication so engine can route end-to-end. Pending Clinical Co-Lead review per CHARTER §6.1 dev-mode signoff exemption.

Used By

Algorithms

Indication